{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=23",
    "query": {
      "intervention": "Low dose Placebo",
      "page": 23
    },
    "page_size": 10
  },
  "pagination": {
    "page": 23,
    "page_size": 10,
    "total_count": 1765,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=24&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+dose+Placebo&page=22&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-22T23:24:11.372Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01323608",
      "title": "The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Thalassemia Major"
      ],
      "interventions": [
        {
          "name": "Vitamin D3",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "6 Years to 60 Years"
      },
      "enrollment_count": 40,
      "start_date": "2011-06",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2011-04-19",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01323608"
    },
    {
      "nct_id": "NCT03205917",
      "title": "A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "PGDM1400/Placebo (3mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400/Placebo (10mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400/Placebo (30mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (3mg/kg + 3mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (10mg/kg + 10mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121/Placebo (30mg/kg + 30mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121 + VRC07-523LS (20mg/kg + 20mg/kg + 20 mg/kg IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PGDM1400 + PGT121 (MTD IV)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "International AIDS Vaccine Initiative",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-10-23",
      "completion_date": "2020-04-20",
      "has_results": false,
      "last_update_posted_date": "2020-09-14",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03205917"
    },
    {
      "nct_id": "NCT07112196",
      "title": "Visugromab in Cachexia International Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Cancer-associated Cachexia"
      ],
      "interventions": [
        {
          "name": "Visugromab (CTL-002)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CatalYm GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 518,
      "start_date": "2026-04-16",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 11,
      "location_summary": "Norwich, Connecticut • Clermont, Florida • Orange City, Florida + 8 more",
      "locations": [
        {
          "city": "Norwich",
          "state": "Connecticut"
        },
        {
          "city": "Clermont",
          "state": "Florida"
        },
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Stuart",
          "state": "Florida"
        },
        {
          "city": "Weston",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07112196"
    },
    {
      "nct_id": "NCT00538850",
      "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fentanyl sublingual spray",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "INSYS Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2007-10",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "Chandler, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538850"
    },
    {
      "nct_id": "NCT02074410",
      "title": "Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington's Disease"
      ],
      "interventions": [
        {
          "name": "OMS643762",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2014-01",
      "completion_date": "2014-10-15",
      "has_results": false,
      "last_update_posted_date": "2018-10-22",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 9,
      "location_summary": "San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02074410"
    },
    {
      "nct_id": "NCT02222324",
      "title": "A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "E2609",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2014-08",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-11-03",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02222324"
    },
    {
      "nct_id": "NCT01411280",
      "title": "Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "methylphenidate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "6 Years to 16 Years"
      },
      "enrollment_count": 34,
      "start_date": "2006-06",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Charleston, South Carolina",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01411280"
    },
    {
      "nct_id": "NCT03860896",
      "title": "GB004 in Adult Subjects With Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ulcerative Colitis"
      ],
      "interventions": [
        {
          "name": "GB004",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 34,
      "start_date": "2019-04-24",
      "completion_date": "2019-12-17",
      "has_results": false,
      "last_update_posted_date": "2020-01-14",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "Monroe, Louisiana",
      "locations": [
        {
          "city": "Monroe",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03860896"
    },
    {
      "nct_id": "NCT04854746",
      "title": "Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Norovirus Infections"
      ],
      "interventions": [
        {
          "name": "VXA-GI.1.NN",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Tablet",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vaxart",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "55 Years to 80 Years"
      },
      "enrollment_count": 66,
      "start_date": "2021-04-26",
      "completion_date": "2022-01-04",
      "has_results": false,
      "last_update_posted_date": "2023-02-13",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 3,
      "location_summary": "Cypress, California • New Orleans, Louisiana • Austin, Texas",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04854746"
    },
    {
      "nct_id": "NCT05227742",
      "title": "Exploratory Study of Low Dose Psilocybin",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Demoralization"
      ],
      "interventions": [
        {
          "name": "Psilocybin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2023-08-15",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-22T23:24:11.372Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05227742"
    }
  ]
}